Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.
Edward Bradley, MD
Advertisement
Articles by Edward Bradley, MD
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.
Advertisement
Latest Updated Articles
Dr. Bradley Discusses Moxetumomab PasudotoxPublished: July 30th 2013 | Updated:
Dr. Bradley on OX40 for the Treatment of CancerPublished: August 28th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5